pancreatic hormone
Glucagon
Answer
Glucagon is authorised or registered in the US, the EU, the UK, Canada, Australia, Switzerland, Brazil, Serbia, Singapore and Turkey: 10 of the 10 registers read. Highest trial phase: Phase 4 (after approval). It has 1,514 registered trials, 351 of them running. Brand names on the FDA label register: Glucagon, Glucagon 1555, Baqsimi and Gvoke Vialdx.
RegulatorTrial register10 regulators' registers, read 2026-09-03 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
1,514 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 263 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 2026 is not complete. 674 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Authorised | EMA, ema | 2026-10-03 |
| United Kingdom | Authorised | MHRA, uk-mhra | 2026-10-03 |
| Canada | Authorised | Health Canada, ca-dpd | 2026-10-03 |
| Australia | Registered | TGA, au-artg | 2026-10-03 |
| Switzerland | Authorised | Swissmedic, ch-swissmedic | 2026-10-03 |
| Brazil | Registado | ANVISA, br-anvisa | 2026-10-03 |
| Serbia | Authorised | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Registered | HSA, sg-hsa | 2026-09-03 |
| Turkey | Ruhsatli | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
CHANGE ALERTS
Get an email when this changes
One email when the status of Glucagon changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 1,514 trials
| NCT06861439 | GLP-1s to Enhance Lasting Optimal Weight running, but no longer enrolling · register updated 2026-10-02 |
|---|---|
| NCT07065552 | Tirzepatide in Obesity-Driven Endometrial Cancer currently recruiting participants · register updated 2026-10-02 |
| NCT05254314 | Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3) running, but no longer enrolling · register updated 2026-10-01 |
| NCT07249554 | Combination Therapy for Alcohol Use Disorder not yet recruiting participants · register updated 2026-10-01 |
| NCT07734792 | Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial not yet recruiting participants · register updated 2026-10-01 |
| NCT06603571 | A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participant completed · register updated 2026-09-29 |
| NCT07527910 | A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD currently recruiting participants · register updated 2026-09-29 |
| 2026-525910-77-00 | Using GLP-1 to prevent Post-Transplantation Diabetes Mellitus no status recorded · register updated 2026-09-28 |
| NCT06745128 | Tirzepatide for Obesity and Meth Use Disorder completed · register updated 2026-09-28 |
| NCT07078838 | Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer not yet recruiting participants · register updated 2026-09-28 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.